These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20082812)

  • 1. Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
    Weinkauf M; Hutter G; Zimmermann Y; Hartmann E; Rosenwald A; Dreyling M
    Talanta; 2010 Feb; 80(4):1539-44. PubMed ID: 20082812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
    Weinkauf M; Zimmermann Y; Hartmann E; Rosenwald A; Rieken M; Pastore A; Hutter G; Hiddemann W; Dreyling M
    Electrophoresis; 2009 Mar; 30(6):974-86. PubMed ID: 19309015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
    Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
    Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
    Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
    Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
    Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
    Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
    Milani V; Lorenz M; Weinkauf M; Rieken M; Pastore A; Dreyling M; Issels R
    Int J Hyperthermia; 2009 Jun; 25(4):262-72. PubMed ID: 19670095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
    O'Connor OA; Moskowitz C; Portlock C; Hamlin P; Straus D; Dumitrescu O; Sarasohn D; Gonen M; Butos J; Neylon E; Hamelers R; Mac-Gregor Cortelli B; Blumel S; Zelenetz AD; Gordon L; Wright JJ; Vose J; Cooper B; Winter J
    Br J Haematol; 2009 Apr; 145(1):34-9. PubMed ID: 19220284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
    Mortenson MM; Schlieman MG; Virudachalam S; Lara PN; Gandara DG; Davies AM; Bold RJ
    Lung Cancer; 2005 Aug; 49(2):163-70. PubMed ID: 16022909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
    Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
    Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
    Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
    Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.